UBE2E3 Antibody

Basic Research Questions

• What detection techniques are compatible with UBE2E3 antibodies?

UBE2E3 antibodies have been successfully employed in multiple molecular techniques. Commercial antibodies include mouse polyclonal (ab66257) suitable for Western blotting, mouse monoclonal [OTI4B4] (ab128098) validated for IHC-P, WB, ICC/IF, and flow cytometry, and rabbit polyclonal antibodies (ab151255, HPA003303) for various applications .

For Western blotting, both monoclonal and polyclonal antibodies can detect UBE2E3 at its predicted molecular weight of 22-23 kDa . The typical dilution range is 1/2000 for rabbit polyclonal antibodies such as ab151255, while monoclonal antibodies like ab128098 have been used at similar concentrations .

For immunofluorescence studies, monoclonal antibodies (e.g., ab128098) perform well at 1/100 dilution in various cell types including HeLa, Jurkat, and HEK-293T cells . For immunohistochemistry, antibodies like HPA003303 have been validated at dilutions of 1:50-1:200 .

• How should I validate the specificity of UBE2E3 antibodies?

Proper validation of UBE2E3 antibodies involves multiple complementary approaches:

Genetic manipulation validation: The gold standard for antibody validation is comparing signal between wild-type samples and those with genetically manipulated UBE2E3 expression. In research examples, siRNA knockdown of UBE2E3 has been used to confirm antibody specificity, with efficiency demonstrated by both qRT-PCR and Western blotting .

Recombinant protein control: Testing antibodies against recombinant UBE2E3 protein can confirm target recognition. Multiple UBE2E3 antibodies have been raised against recombinant fragments of human UBE2E3, including regions within amino acids 50-200 or the full-length protein .

Molecular weight verification: UBE2E3 has a predicted band size of 22 kDa in Western blot analysis. Observing a predominant band at this molecular weight supports antibody specificity .

Immunodepletion test: As demonstrated in NRF2 research, antibody specificity can be verified by immunodepleting UBE2E3 from lysates and comparing with mock-depleted samples in subsequent assays .

• What sample preparation methods optimize UBE2E3 detection?

Sample preparation varies by technique and research question:

For Western blot analysis: Total cell lysates should be prepared in SDS lysis buffer and separated by SDS-PAGE. Studies have successfully used PVDF membranes blocked with 5% defatted milk for 1 hour at room temperature . Efficient protein transfer and appropriate blocking are critical for minimizing background and enhancing specific signal.

For immunofluorescence: Fixation with paraformaldehyde followed by permeabilization is effective. For subcellular localization studies of UBE2E3 and its interaction partners (e.g., NRF2), it's crucial to avoid fixation artifacts by testing multiple fixation protocols .

For flow cytometry: Intracellular staining protocols have been successfully employed with UBE2E3 antibodies (e.g., ab128098) at 1/100 dilution in multiple cell lines including HeLa, Jurkat, and HEK-293T cells .

For BMSCs studies: When investigating UBE2E3 in bone marrow stromal cells, special attention should be paid to isolation protocols to ensure cell purity. Age-matched samples from young and old animals have been used to study age-related UBE2E3 expression changes .

• What biological controls should be incorporated in UBE2E3 antibody experiments?

Positive tissue controls: Based on GTEx data, bone marrow samples serve as excellent positive controls as UBE2E3 is highly expressed in this tissue . This makes bone marrow-derived cells like BMSCs particularly suitable for UBE2E3 studies.

Negative controls for immunostaining: When performing ICC/IF or IHC, include isotype-matched nonspecific antibody controls. For example, flow cytometry analysis has demonstrated the specificity of UBE2E3 antibody (ab128098) compared to a nonspecific negative control antibody .

Knockdown/overexpression controls: UBE2E3 expression can be manipulated using siRNA for knockdown or expression plasmids for overexpression. Both approaches have been validated in multiple studies and provide critical controls for antibody specificity .

Age-matched controls: When studying age-related changes in UBE2E3 expression, age-matched controls are essential. Research has shown that UBE2E3 expression decreases with age in BMSCs, making this an important variable to control .

Advanced Research Questions

• How can UBE2E3 antibodies be employed to study protein-protein interactions?

UBE2E3 forms functional complexes with several proteins, and various techniques can investigate these interactions:

Co-immunoprecipitation: UBE2E3 antibodies have been successfully used in co-IP experiments to study interactions with partners like Nedd4-2. In renal mpkCCD cl4 cells, Nedd4-2 and UBE2E3 were co-immunoprecipitated, confirming their interaction in ENaC regulation .

DNA affinity precipitation assays: These assays can assess how UBE2E3 affects transcription factor binding to promoter sequences. For example, UBE2E3's role in NRF2 binding to the ARE sequence from the NQO1 promoter was studied using biotinylated DNA probes and streptavidin affinity matrix combined with UBE2E3 antibodies .

Proximity ligation assays: While not explicitly mentioned in the provided materials, this technique could be adapted using UBE2E3 antibodies to visualize protein-protein interactions in situ with single-molecule resolution.

Yeast two-hybrid validation: UBE2E3 was initially identified as an interactor with Nedd4-2 through a two-hybrid screen. This interaction was subsequently validated using co-IP with UBE2E3 antibodies . Similar approaches could be applied to study other potential interaction partners.

The choice of UBE2E3 antibody is critical - monoclonal antibodies often provide higher specificity for IP experiments, while polyclonal antibodies may offer better sensitivity for detecting less abundant complexes.

• What methodologies can elucidate UBE2E3's role in ubiquitination pathways?

UBE2E3 catalyzes 'Lys-11', 'Lys-48', and 'Lys-63'-linked polyubiquitination in vitro . Several approaches can investigate its function:

In vitro ubiquitination assays: UBE2E3 has been shown to transfer ubiquitin to Nedd4-2 and act in concert with this enzyme in the ubiquitination of bacterial proteins in vitro . Similar assays can be designed using purified components and UBE2E3 antibodies to detect the enzyme in reaction mixtures.

Site-directed mutagenesis: Catalytically inactive mutants of UBE2E3 (UBE2E3-CS) can be created to study the role of its enzymatic activity. These mutants have been used to demonstrate that UBE2E3 affects ENaC activity in Xenopus oocytes .

Ubiquitination target identification: UBE2E3 family members can enhance the ubiquitination of TDP-43, relevant to neurodegenerative diseases . Immunoprecipitation with UBE2E3 antibodies followed by mass spectrometry can identify novel ubiquitination targets.

Linkage-specific ubiquitin antibodies: These can be used in conjunction with UBE2E3 antibodies to determine the type of polyubiquitin chains (K11, K48, K63) formed on specific substrates in cellular contexts.

A comprehensive experimental design would include both gain-of-function (overexpression) and loss-of-function (siRNA knockdown) approaches, with UBE2E3 antibodies used to confirm expression levels and identify ubiquitinated protein substrates.

• How can UBE2E3's role in cellular senescence be investigated?

UBE2E3 regulates cellular senescence in BMSCs, with its knockdown promoting senescence and its overexpression attenuating it . Methodological approaches include:

SA-β-galactosidase staining: This classic senescence marker increases in UBE2E3 knockdown cells. Quantification of SA-β-gal positive cells provides a robust measure of senescence induction .

Senescence marker expression: qRT-PCR for senescence markers like p16 and p21 has been used to assess senescence following UBE2E3 manipulation. Both markers increase when UBE2E3 is knocked down .

Passage-dependent expression analysis: UBE2E3 expression gradually decreases with increasing passage number in mice BMSCs, correlating with cellular aging. Western blot and qRT-PCR can track this change .

Comparative analysis of young vs. old tissues: UBE2E3 expression is significantly lower in BMSCs from old animals compared to young ones. This can be assessed using qRT-PCR and Western blot with UBE2E3 antibodies .

Cell cycle analysis: UBE2E3 depletion causes cell cycle arrest characterized by increased p27Kip1. Flow cytometry with UBE2E3 antibodies can establish connections between UBE2E3 levels, cell cycle status, and senescence onset .

These methods can be combined with mitochondrial phenotyping, as UBE2E3 depletion causes perinuclear accumulation of mitochondria distinct from other senescence-inducing conditions .

• What experimental approaches can elucidate UBE2E3's function in NRF2 signaling?

UBE2E3 regulates the localization and activity of NRF2, an antioxidant transcription factor . Research methodologies include:

Target gene expression analysis: qRT-PCR can measure expression of NRF2 target genes (NQO1, GCLC, GCLM, HO-1) following UBE2E3 manipulation. UBE2E3 knockdown reduces both basal and oxidant-induced transcriptional activity of NRF2 .

DNA affinity precipitation assays: These assess how UBE2E3 affects NRF2 binding to promoter sequences. Biotinylated DNA probes representing ARE sequences can be used with streptavidin affinity matrix .

Subcellular localization studies: Immunofluorescence with UBE2E3 and NRF2 antibodies can track NRF2 translocation. UBE2E3 depletion reduces nuclear NRF2 and causes its accumulation at perinuclear "hot spots" .

Oxidative stress response: Cells can be treated with tBHQ, a prooxidant that stabilizes and activates NRF2, to study how UBE2E3 affects stress responses .

Protein-protein interaction analysis: Co-IP with UBE2E3 antibodies can identify interactions between UBE2E3, NRF2, and other regulatory proteins like importin-11 or KEAP1 .

These approaches can be complemented with chromatin immunoprecipitation (ChIP) assays to directly measure NRF2 occupancy at target gene promoters following UBE2E3 manipulation.

• How can UBE2E3 antibodies be utilized in studies of bone formation and osteoporosis?

UBE2E3 is highly expressed in bone marrow and positively associated with osteogenesis-related genes . Research approaches include:

Gene co-expression analysis: UBE2E3 is positively correlated with osteogenic genes (RUNX2, COL1A1, BMP2, FOXP1, ALPL, BGLAP, TAZ) in normal tissues. This can be validated in experimental systems using UBE2E3 antibodies combined with antibodies against these markers .

Osteogenic differentiation assays: ALP staining and Alizarin Red S (ARS) staining can assess how UBE2E3 manipulation affects osteogenic differentiation. UBE2E3 knockdown inhibits osteogenic differentiation of young BMSCs .

Clinical sample analysis: UBE2E3 expression is significantly decreased in BMSCs from osteoporosis patients. Western blotting with UBE2E3 antibodies can be used to analyze clinical samples .

Age-related expression changes: The reduction of UBE2E3 with aging can be studied in BMSCs from different age groups. Both qRT-PCR and Western blot approaches have been validated for this purpose .

Single-cell sequencing validation: Single-cell data showing reduced UBE2E3 expression in BMSCs from old rats can be validated using immunofluorescence with UBE2E3 antibodies to assess expression heterogeneity within BMSC populations .

These methodologies can help establish UBE2E3 as a potential biomarker and therapeutic target for age-related bone disorders including osteoporosis.

• What methods can investigate UBE2E3's involvement in neurodegenerative disease mechanisms?

UBE2E3 is a functional interactor of TDP-43, a protein that forms aggregates in frontotemporal lobar degeneration and amyotrophic lateral sclerosis . Research approaches include:

Protein interaction validation: Co-immunoprecipitation with UBE2E3 antibodies can confirm interaction with TDP-43 in neural cell models. This interaction was initially identified in a yeast two-hybrid screen and confirmed by co-IP .

Ubiquitination assays: UBE2E3 family members can enhance TDP-43 ubiquitination. Immunoprecipitation of TDP-43 followed by Western blotting with ubiquitin antibodies can assess how UBE2E3 affects its ubiquitination status .

Proteasome inhibition studies: When cells are treated with proteasome inhibitors, ubiquitinated and insoluble TDP-43 species accumulate. Western blotting with UBE2E3 antibodies can assess how UBE2E3 levels affect this process .

Protein aggregation analysis: Immunofluorescence and biochemical fractionation can determine how UBE2E3 affects TDP-43 aggregation. UBE2E3 antibodies can be used to track the co-localization of the enzyme with TDP-43 aggregates .

In vivo models: Drosophila models have been used to study TDP-43 aggregation. Immunohistochemistry with UBE2E3 antibodies can assess enzyme expression in these models .

These approaches can help establish whether modulation of UBE2E3 activity might represent a therapeutic strategy for TDP-43 proteinopathies and other neurodegenerative conditions.